| Identification | Back Directory | [Name]
2,9-Diazaspiro[5.5]undecan-1-one, 2-(1H-indol-3-ylMethyl)-9-(4-Methoxy-2-pyriMidinyl)- | [CAS]
1373765-19-5 | [Synonyms]
IPSU
2-(1H-Indol-3-ylmethyl)-9-(4-methoxy-2-pyrimidinyl)-2,9-diazaspiro[5.5]undecan-1-one
2-((1H-indol-3-yl)methyl)-9-(4-methoxypyrimidin-2-yl)-2,9-diazaspiro[5.5]undecan-1-one
2,9-Diazaspiro[5.5]undecan-1-one, 2-(1H-indol-3-ylMethyl)-9-(4-Methoxy-2-pyriMidinyl)- | [EINECS(EC#)]
604-604-1 | [Molecular Formula]
C23H27N5O2 | [MDL Number]
MFCD25976654 | [MOL File]
1373765-19-5.mol | [Molecular Weight]
405.49 |
| Chemical Properties | Back Directory | [Boiling point ]
702.0±70.0 °C(Predicted) | [density ]
1.32±0.1 g/cm3(Predicted) | [storage temp. ]
Store at -20°C | [solubility ]
DMSO:30.0(Max Conc. mg/mL);73.98(Max Conc. mM) | [form ]
A crystalline solid | [pka]
16.94±0.30(Predicted) | [color ]
White to off-white |
| Hazard Information | Back Directory | [Uses]
IPSU is a novel orexin (OX2) receptor antagonists for insomnia treatment. | [in vivo]
IPSU has low blood clearance, shows high maximal blood exposure and AUC after oral dosing. It exhibits an acceptable absolute oral bioavailability and a brain/blood concentration ratio that indicated favorable brain penetration. IPSU increases sleep when dosed during the mouse active phase (lights off); IPSU induces sleep primarily by increasing NREM sleep. IPSU shows a fast onset of action, with a clear increase in total sleep time during the first hour afterdosing. The effect lasts 4-5 h, after which time the total sleep time per hour is the same as on vehicle day [1]. | [storage]
Store at -20°C |
|
| Company Name: |
BOC Sciences
|
| Tel: |
|
| Website: |
https://www.bocsci.com |
|